Ardelyx appoints Mark Kaufmann as chief business officer

Role includes business development, licensing and strategic planning

Ardelyx, a US developer of oral therapeutics to correct metabolic disorders, has appointed Mark Kaufmann to the newly created position of chief business officer. The role at the Fremont, CA company will include business and corporate development, licensing, and strategic planning.

Kaufmann was formerly chief executive of Allostera and Celmed BioSciences.

‘Mark’s deep understanding of the biotechnology business, coupled with his substantial experience at the most senior levels in business development and planning will serve Ardelyx well during our next phase of corporate development,’ said Mike Raab, chairman and ceo of Ardelyx.

Kaufmann has more than 20 years of experience in the biopharmaceutical industry in the US and Canada in business and corporate development roles.

Most recently, he was president and ceo of Allostera Pharma, a venture-backed, preclinical company focused on autoimmune diseases.

Prior to joining Allostera, Kaufmann was president and ceo of Celmed BioSciences, where he was responsible for raising funds and selling the company to Kiadis Pharma, a European biotechnology company. He has also held roles at Nexia Biotechnologies, Conceptis Technologies and MedImmune.

You may also like

Ingredients

Therapeutic: tenapanor for hyperphosphataemia

Patients with chronic kidney disease being treated with dialysis are at risk of developing hyperphosphataemia. This elevation of phosphorus levels is associated with cardiovascular morbidity and mortality
Manufacturing

Virica Biotech and FUJIFILM Biosciences collaborate to boost AAV vector yields in HEK293 manufacturing system

Virica Biotech has announced a collaboration with FUJIFILM Biosciences to co-develop an off-the-shelf enhancer-media solution combining Virica's VSE technology with FUJIFILM's BalanCD HEK293 system, targeting improved AAV productivity and process robustness for gene therapy manufacturers
Marketing

Ofichem consolidates six brands into single integrated CDMO and pharmaceutical supplier identity

Dutch family-owned pharmaceutical company Ofichem has unified its six business units — spanning API, drug substance, drug product and distribution — under a single trading name
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Accelerating the development of bispecific antibodies

Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains how the use of comprehensive tailored approaches can enhance bispecific antibody productivity, stability and quality while accelerating their delivery to market
Analysis

Conjugation chemistry key to unlocking next-generation oligonucleotide therapies, says Bachem

As demand for oligonucleotide therapeutics accelerates, Bachem's Director of Oligonucleotide Production explains how conjugation chemistry is helping CDMOs overcome delivery challenges
Manufacturing

UK pharmaceutical manufacturers struggling to meet F-Gas compliance amid ageing cooling infrastructure

A new Aggreko report reveals that nearly all UK pharmaceutical manufacturers are facing barriers to upgrading cooling systems ahead of the accelerating F-Gas phase-down timeline
Regulatory

UK REACH ATRm: CBA welcomes progress but warns of significant hurdles ahead

The Chemical Business Association has acknowledged long-awaited movement on the UK REACH Alternative Transitional Registration model following DEFRA's consultation response, but cautioned that cost burdens likely running into hundreds of millions of pounds
Subscribe now